Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

Share Price is delayed by 15 minutes
Get Live Data
0.51    0.00 (0.00%)
Bid:
0.51
Ask:
0.516
Spread: 0.006 (1.176%)
Market Cap: $296.48m
IDHC Live PriceLast checked at - London Stock Exchange

Intraday Int Diag Hld Share Chart

Form 8.3 - Integrated Diagnostics Holdings plc

24 Jun 2026 09:26

Norges Bank - Form 8.3 - Integrated Diagnostics Holdings plc

Norges Bank - Form 8.3 - Integrated Diagnostics Holdings plc

PR Newswire

LONDON, United Kingdom, June 24

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Norges Bank
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Integrated Diagnostics Holdings plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 23/06/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: USD 0.25 ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 14,172,788 2.44
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL: 14,172,788 2.44

* Norges Bank does not have discretion over dealing and offer acceptance decisions with respect to 14,172,788 shares that are included in the total above.

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b) Cash-settled derivative transactions

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure:

24/06/2026
Contact name: Philippe Chiaroni
Telephone number*: +4724073000

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk .



Date   Source Headline
24th Apr 20253:30 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20257:00 amRNSFinal Results
10th Apr 20254:41 pmRNSNotice of Results
9th Dec 202410:59 amRNSIDH INCREASES STAKE IN BIOLAB KSA
14th Nov 20247:00 amRNS3rd Quarter Results
11th Nov 202411:29 amRNSNotice of Results
8th Oct 20245:21 pmRNSCancellation of Treasury Shares
1st Oct 20249:00 amRNSTotal Voting Rights
18th Sep 20244:14 pmRNSCompletion of Treasury Shares Removal Process
6th Sep 20247:00 amRNSUpdate on Treasury Shares Removal Process
5th Sep 20247:00 amRNSCompletion of EGX Delisting
28th Aug 20247:00 amRNSHalf-year Report
27th Aug 20247:00 amRNSEGX Delisting – buyback under EGX's OPR
23rd Aug 20241:30 pmRNSNotice of Results
13th Aug 20247:00 amRNSEGX Delisting – timeline under EGX's OPR
18th Jul 20243:45 pmRNSResults of Extraordinary General Meeting
1st Jul 20243:40 pmRNSPublication of Circular and Notice of EGM
27th Jun 20247:00 amRNSIDH's proposed revised Delisting Buyback Price
12th Jun 20243:35 pmRNSResults of Extraordinary General Meeting
30th May 20247:00 amRNS1ST QUARTER RESULTS
29th May 20243:44 pmRNSResult of AGM
28th May 202410:42 amRNSNotice of Results
24th May 20244:16 pmRNSPublication of Circular and Notice of EGM
16th May 20247:00 amRNSIDH proposing to delist its shares from the EGX
30th Apr 20242:13 pmRNSNotice of AGM
4th Apr 20241:55 pmRNSAnnual Financial Report
28th Mar 20247:00 amRNSFinal Results
26th Mar 20249:15 amRNSNotice of Results
18th Jan 20244:03 pmRNSIDH appoints Group CFO, VP and Board Member
16th Nov 20237:00 amRNS3rd Quarter Results
25th Oct 20237:00 amRNSIDH CEO increases stake in the Company
17th Oct 20231:56 pmRNSDirector/PDMR Shareholding
16th Oct 202312:26 pmRNSDirector/PDMR Shareholding
13th Oct 20232:02 pmRNSDirector/PDMR Shareholding
12th Oct 202310:33 amRNSDirector/PDMR Shareholding
11th Oct 202310:45 amRNSDirector/PDMR Shareholding
31st Aug 20237:00 amRNSHalf-year Report
30th Aug 20239:57 amRNSNotice of Results
21st Jun 202311:18 amRNSCFO & Strategic Investment Officer Appointments
14th Jun 20233:01 pmRNSDirector/PDMR Shareholding
1st Jun 20237:00 amRNS1st Quarter Results
30th May 20235:49 pmRNSResult of AGM
4th May 20233:03 pmRNSAnnual Financial Report & Notice of AGM
28th Apr 20234:01 pmRNSDirector/PDMR Shareholding
18th Apr 20233:23 pmRNSDirector/PDMR Shareholding
6th Apr 202311:05 amRNSFinal Results
6th Apr 20237:00 amRNSPreliminary Results
4th Apr 20236:10 pmRNSNotice of Results
21st Feb 20234:35 pmRNSPrice Monitoring Extension
6th Feb 20234:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.